Immunotherapy for ovarian cancer is improved by tumor targeted delivery of a neoantigen surrogate
L. R. Scanlon, L. Gabor, O. R. Khouri, S. Ahmad, E. Levy, E. Buckley, A. Ouedraogo, D. Y.-S. Kuo, K. Lin, N. Nevadunsky, S. Isani, S. Sun, C. Gravekamp
This study shows that delivering a neoantigen surrogate via Listeria monocytogenes combined with gemcitabine and anti-PD1 improves ovarian cancer treatment in mice.
bioRxiv · Oct 11, 2023 · PreprintCancer Biology